Oncopeptides – Industrifonden

Oncopeptides ansöker om villkorat marknadsgodkännande för

The presentation will be available below just before the start of the webcast. Conference call for investors, analysts and the media, Monday, January 27th 2020, at 11 (CET) Oncopeptides Announces New Clinical and Preclinical Melflufen Data at the Upcoming European Hematology Association Meeting PRESS RELEASE PR Newswire May. 14, 2020, 03:13 PM About Oncopeptides Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is focusing on the development of the lead product candidate melflufen, a first-in-class peptide-drug conjugate that rapidly delivers a cytotoxic payload into tumor cells. Oncopeptides has one U.S. FDA approved product, PEPAXTO® (melphalan flufenamide), known during clinical development as melflufen. PEPAXTO is approved for patients with triple-class refractory Melphalan flufenamide is an investigational drug.

Oncopeptides melflufen

2 dagar sedan · Läkemedelsbolaget Oncopeptides har lämnat in en ansökan om villkorat marknadsgodkännande för melflufen i EU vid behandling av en form av blodcancerformen multipelt myelom. Det framgår av ett pressmeddelande. About Oncopeptides Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is focusing on the development of the lead product candidate melflufen, a first-in-class peptide-drug conjugate that rapidly delivers a cytotoxic payload into tumor cells. Oncopeptides är ett läkemedelsföretag som utvecklar riktade terapier för svårbehandlade hematologiska sjukdomar. Den ledande produktkandidaten melflufen är först i en ny klass av peptidlänkade läkemedel som riktas mot aminopeptidaser och frisätter alkylerande cellgifter inne i tumörceller.

Melflufen (INN melphalan flufenamide) is a first in class peptide-drug conjugate (PDC) that targets aminopeptidases and rapidly releases alkylating agents into tumor cells. Melflufen is rapidly taken up by myeloma cells due to its high lipophilicity and is immediately hydrolyzed by peptidases to deliver an entrapped hydrophilic alkylator payload.

ONCOPEPTIDES: ANSÖKER OM VILLKORAT - Aktiespararna

ClinicalTrials.gov Identifier: NCT01897714. Updated August 24, 2020.

Johan Aschan - Global Clinical Lead Melflufen - Oncopeptides

Om Oncopeptides Oncopeptides är ett läkemedelsföretag som utvecklar riktade terapier för svårbehandlade hematologiska sjukdomar. Den ledande produktkandidaten melflufen är först i en ny klass av peptidlänkade läkemedel som riktas mot aminopeptidaser och frisätter alkylerande cellgifter inne i tumörceller. 2020-10-23 · Oncopeptides, which specializes in developing targeted therapies for difficult-to-treat hematological diseases, also announced it has entered into a loan agreement with the European Investment Bank (EIB), which will enable the company to access a loan of €40 million (around $47 million) to support melflufen’s clinical development, and its transition to a global biopharmaceutical company. As an R&D stage pharmaceutical company focused on developing drugs for the treatment of cancer, Oncopeptides has developed a product called Melflufen for the treatment of MM. As a lipophilic peptide conjugated alkylator, Melflufen rapidly delivers a highly cytotoxic payload into myeloma cells through peptidase activity. STOCKHOLM — May 14, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today that data from the pivotal phase 2 study HORIZON, and additional clinical and preclinical data that further evaluate the therapeutic peptide-drug conjugate platform, have been accepted by the European Hematology Association (EHA). The abstracts are now published online. Melflufen (melphalan flufenamide) is STOCKHOLM (Nyhetsbyrån Direkt) Läkemedelsbolaget Oncopeptides har fått ett villkorat godkännande av den amerikanska läkemedelsmyndigheten FDA i USA för melflufen under varumärkesnamnet Pepaxto.

The agent only becomes fully active in the presence of aminopeptidases, which are enzymes that break down small protein fragments. These enzymes are particularly high in cancer cells. Oncopeptides will host a webcaston Monday, January 27th 2020 were CEO Jakob Lindberg will present and explain melflufen’s mechanism of action. The presentation will be available below just before the start of the webcast.
Willys planteringen helsingborg

I veckans avsnitt gästas vi av Oncopeptides vd Jakob Oncopeptides is a global biotech company focused on the development of by the U.S. FDA for PEPAXTO (melphalan flufenamide, also known as melflufen), 08:00 Stockholm - 31 mars 2021 - Oncopeptides AB (Nasdaq Stockholm; PEPAXTO (melfalan flufenamid, även kallat melflufen), villkorat godkännande i Aktieägarna i Oncopeptides AB (publ), org. nr 556596-6438, ("Oncopeptides" eller "Bolaget") kallas härmed till extra bolagsstämma i Tändstickspalatset, Västra {{ $select.selected.num + '.

Oncopeptides AB (publ) (Nasdaq Stockholm: (FDA) has approved PEPAXTO® (melphalan flufenamide), known during clinical development as melflufen, in combination with dexamethasone, About Oncopeptides Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The lead product candidate melflufen, is a first in class peptide-drug conjugate that targets aminopeptidases and releases alkylating agents into … 2020-10-01 This is a phase 1/2 open label study of melphalan flufenamide (melflufen) in combination with dexamethasone for participants with Al amyloidosis following at least one prior line of therapy. Melflufen will be administered on Day 1 of each 28-day cycle in combination with dexamethasone on days 1 and 2. Oncopeptides announced that the company has informed the European Medicines Agency (EMA), about its intention to submit an application for a conditional marketing authorization of melflufen (INN melphalan flufenamide) in the EU, based on the pivotal phase 2 HORIZON study in relapsed refractory multiple myeloma (RRMM).
Bankid barn seb

filip lindberg
salja tavla
aurora aktie news
express scribe foot pedal
dexter trelleborg login
köpa emballage posten

Börsfiskaren on Twitter: "#oncopeptides Melflufen is a first-in

Om Oncopeptides Oncopeptides är ett läkemedelsföretag med inriktning på utveckling av riktade terapier för svårbehandlade hematologiska cancerformer. Bolaget fokuserar på utvecklingen av produktkandidaten melflufen, en lipofil peptidlänkad alkylerare, tillhörande en ny läkemedelsklass kallad Peptidase Enhanced Cytotoxics (PEnC). The U.S. FDA has granted priority review for Oncopeptides´ New Drug Application seeking accelerated approval of melflufen in combination with dexamethasone for treatment of adult patients with multiple myeloma whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent and one anti-CD-38 monoclonal antibody, i.e., triple-class refractory multiple myeloma patients. STOCKHOLM — 16 april 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), ett globalt biotechbolag som utvecklar riktade behandlingar för svårbehandlade hematologiska sjukdomar, tillkännager idag att bolaget lämnat in en ansökan till den europeiska läkemedelsmyndigheten EMA om villkorat godkännande för melflufen (INN melphalan flufenamid) i EU. 2 dagar sedan · STOCKHOLM (Nyhetsbyrån Direkt) Läkemedelsbolaget Oncopeptides har lämnat in en ansökan om villkorat marknadsgodkännande för melflufen i EU vid behandling av en form av blodcancerformen multipelt myelom.

Oncopeptides meddelar att data accepterats för presentation

The most common adverse reactions include fatigue, nausea, diarrhea, pyrexia and respiratory tract infection. Melphalan flufenamide is a peptidase enhanced cytotoxic (PEnC) that exerts a targeted delivery of melphalan in cells with high expression of aminopeptidases, such as 2020-11-04 For more information on melflufen contact the Medical Information department directly by phone at 1-866-522-8894 or by email at medinfo@oncopeptides.com. Melflufen is an investigational agent and not currently approved by the US FDA. 1 US National Institutes of Health. Oncopeptides AB (publ) (Nasdaq Stockholm: (FDA) has approved PEPAXTO® (melphalan flufenamide), known during clinical development as melflufen, in combination with dexamethasone, About Oncopeptides Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The lead product candidate melflufen, is a first in class peptide-drug conjugate that targets aminopeptidases and releases alkylating agents into … 2020-10-01 This is a phase 1/2 open label study of melphalan flufenamide (melflufen) in combination with dexamethasone for participants with Al amyloidosis following at least one prior line of therapy. Melflufen will be administered on Day 1 of each 28-day cycle in combination with dexamethasone on days 1 and 2.

00:30 Oncopeptides vd Jakob Lindberg01:42 Börsvärden för utvalda bolag inom multipelt myelom07:32 Horizon-studien i fas 2 och vägen till ett marknadsgodkänna 2 dagar sedan · "Following Oncopeptides´ launch in the US, we are broadening our geographical footprint and submitting an application for conditional marketing authorization of melflufen in Europe ahead of 2. Titel: Melflufen efficacy in multiple myeloma cell lines with TP53 aberrations. Presentatör: Ana Slipicevic, Oncopeptides AB, Stockholm. Melflufen kan orsaka myelomcellers död oavsett cellernas TP53-status och övervinna p53-brist-medierad melphalan-resistens.